Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 24 Mar, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Articles
- NASA to Spend $20 Billion on Moon Base, Cancel Lunar Orbit Station
- Pakistan Offers to Host Actual Peace Talks—IRL
- Mandopop Legend Jay Chou to Release First Album in 4 Years
- Japan's Cherry Blossom Picnics Pinched by 25% Food Inflation Since 2020
- SK Hynix Places Record $8 Billion Order for ASML EUV Lithography Tools
- TSMC Capacity a Major Bottleneck for AI Buildout Says Broadcom
- BTS Army to Bring $5.3 Billion Spending Power to a City Near You
- Zoox to Expand Robotaxi Service into San Francisco and Las Vegas
- NYSE Partners with Securitize to Develop Tokenized Securities Platform
- World's 25 Most Polluted Cities All in India, Pakistan and China